阿帕替尼联合同步放化疗治疗中晚期宫颈癌的研究  

Clinical Efficacy of Apatinib Combined with Concurrent Chemoradiotherapy in the Treatment of Advanced Cervical Cancer

作　　者：饶林丽 夏常青 谢兆光 王翔宇[1,4] 张婷婷 崔春辉 陈金龙 魏玲 王兴武 孙丽 刘乃富 RAO Linli;XIA Changqing;XIE Zhaoguang;WANG Xiangyu;ZHANG Tingting;CUI Chunhui;CHEN Jinlong;WEI Ling;WANG Xingwu;SUN Li;LIU Naifu(School of Medicine and Life Sciences,Shandong Academy of Medical Sciences,Jinan University,Jinan,Shandong,250022,China;Department of Gynecologic Oncology,Shandong Cancer Hospital Affiliated to Shandong University,Shandong Academy of Medical Sciences,Jinan,Shandong,250117,China;Department of Anorectal,Huaiyin District People’s Hospital of Jinan,Jinan,Shandong,250000,China;Department of Obstetrics and Gynecology,Central Hospital of Fengxian District,Shanghai,201400,China)

机构地区：[1]济南大学·山东省医学科学院医学与生命科学学院,山东济南250022 [2]山东大学附属山东省肿瘤医院妇瘤科,山东省医学科学院,山东济南250117 [3]济南市槐荫区人民医院肛肠科,山东济南250000 [4]上海市奉贤区中心医院妇产科,上海201400

出　　处：《肿瘤药学》2018年第5期767-771,共5页Anti-Tumor Pharmacy

基　　金：山东省重点研发计划(NO.2018GSF118238);山东省医药卫生科技发展计划(NO.2016WSA18028);山东省医科院项目(NO.2016-06);山东省卫生厅课题(NO.2011HZ097);山东省自然基金课题(NO.ZR2012HM010)

摘　　要：目的探讨阿帕替尼联合同步放化疗治疗中晚期宫颈癌的临床疗效和不良反应。方法选择我院2016年7月-2017年7月收治的40例中晚期宫颈癌患者为研究对象,按随机数字表法分为试验组和对照组,各20例。对照组接受同步放化疗治疗,试验组在同步放化疗基础上联合阿帕替尼治疗。观察并分析两组患者的治疗效果和不良反应。结果对照组患者治疗总有效率为40%,试验组为75%,差异有统计学意义(P<0.05)。试验组中位总生存期为19.88个月,对照组为10.68个月,组间生存状况分布差异有统计学意义(P<0.05)。两组患者治疗过程中的主要不良反应包括乏力、高血压、蛋白尿、手足综合征、骨髓抑制、腹泻、头痛、皮疹等,多为0-Ⅱ度,不良反应总发生率组间比较差异无统计学意义(P>0.05)。结论阿帕替尼联合同步放化疗可提高中晚期宫颈癌患者的治疗效果,且不良反应可耐受,值得临床推广。Objective To investigate the effectiveness and safety of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods Forty patients with middle and advanced cervical cancer who were treated in our hospital between July 2016 and July 2017 were selected. They were randomly divided into test group and control group with 20 patients in each group. The control group received concurrent chemoradiotherapy. The test group was treated with apatinib on the basis of concurrent chemoradiotherapy. The clinical benbfits and side effects of the two groups were observed and analyzed. Results The total effective rate was 75% in the test group and 40% in the control group; the difference was statistically significant(P<0.05). The test group had a median survival time of 19.88 months, and the control group had the median survival time of only 10.68 months. There were significant difference in survival time between the two groups(P<0.05). The main adverse reactions during the treatment included fatigue, hypertension, proteinuria, hand-foot syndrome, myelosuppression, diarrhea, headache and rash, but most of them were of 0-Ⅱ degrees. No statistical differences were found between the two groups in the overall incidence rate of adverse reactions(P>0.05). Conclusion Apatinib combined with concurrent chemoradiotherapy can improve the therapeutic effect of patients with middle and advanced cervical cancer. The adverse reactions are well tolerated. So it is worthy of promotion in clinical practice.

关 键 词：阿帕替尼 宫颈癌 中晚期 同步放化疗 

分 类 号：R737.33[医药卫生—肿瘤]